

Rexanna's Foundation - Funded Research Projects in 2017

Research Study	Researcher(s)	Institution	Benefit to Patients
Focusing on biomarkers for personalizing immunotherapy in early stage lung cancer - this includes microbiome and blood-based markers	Boris Sepesi, M.D.	The University of Texas MD Anderson Cancer Center	To determine which patients will likely benefit or experience toxicities from our new immunotherapy studies.
Research Study	Researcher(s)	Institution	Benefit to Patients
Focusing of biomarkers for personalizing immunotherapy in metastatic lung cancer this includes autoantibodies and genomic markers	Mehmet Altan, M.D. & Boris Sepesi, M.D.	The University of Texas MD Anderson Cancer Center	To improve patient selection of who will likely benefit or experience toxicities from our new immunotherapy studies.
Research Study	Researcher(s)	Institution	Benefit to Patients
Correlate the microorganisms in the gut with the risk of inflammation of the colon and response to immunotherapy.	Mehmet Altan, M.D.	The University of Texas MD Anderson Cancer Center	To learn the impact of modifying the gut microbiome to impact response rates to immunotherapy and protect patients from colon inflammation.
Research Study	Researcher(s)	Institution	Benefit to Patients
Research on oligometastatic lung cancer. Traditionally this cancer has only spread to a limited number of sites. Historically patients have only been treated with chemo. The study is to determine the biomarkers for selecting which patients benefit from aggressive local consolidative therapy.	Daniel Gomez, M.D. & Jianjun Zhang, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center	To determine which patients could receive major benefit from surgery and radiation in addition to systemic therapy.
Research Study	Researcher(s)	Institution	Benefit to Patients
To understand how EGFR/HER2 exon 20 mutant non-small cell lung cancer develop resistance to poziotinib.	Jacqulyne Robichaux, Ph.D.	The University of Texas MD Anderson Cancer Center	Patients who have tumors that become resistant to treatments, the goal is to provide them new combinations of drugs to overcome it.